Milford Molecular Diagnostics

2044 Bridgeport Ave, Milford, CT 06460

 


Milford Molecular Diagnostics


"DNA sequencing-based diagnostics are our specialty and routine diagnostic DNA sequencing is the gateway to practicing personalized molecular medicine."


- Sin Hang Lee, MD, F.R.C.P.(C), FCAP

Early Lyme Disease Laboratory Diagnosis

Lyme disease, a systemic bacterial infection caused by Borrelia burgdorferi (B. burgdorferi), is the most common tickborne disease in the United States. Released 2010–2018 insurance records suggest that each year approximately 476,000 Americans are diagnosed and treated for Lyme disease. But the true number of Lyme disease patients is unknown due to the lack of reliable sensitive and specific routine laboratory diagnostic tools. It is believed that at the early stage of infection this disease can be treated successfully with a proper course of antibiotics, but the spirochete bacteria may disseminate from the site of the tick bite to other regions of the body if not timely and properly treated. In the opinion of a group of experts, common FDA-cleared serology tests miss a large number of early Lyme disease cases, and novel diagnostics that improve laboratory confirmation for early Lyme disease are urgently needed [1]. Now, this need has been met by Sanger sequencing of specific B. burgdorferi chromosomal genes in patient’s platelet pellets.

For the past 20 years, the scientists in Milford Molecular Diagnostics Laboratory, formerly affiliated with Milford Hospital in Connecticut, have focused on developing Sanger sequencing methods for routine diagnosis of infectious diseases, in particular for Lyme disease [2-9]. To perform diagnostic Sanger sequencing, one must first extract the nucleic acids from a complex human specimen and use polymerase chain reaction (PCR) to selectively amplify (exponentially duplicate) a segment of the pathogen’s nucleic acid many billion-folds, and use the amplified pathogen DNA as the template for sequencing. The sequencing instrument computer generates an electropherogram as one illustrated below, for example, showing the four-letter nucleotide base sequence. Submission of this 311-base sequence to the GenBank for an enquiry induces a GenBank report confirming that a segment of Borrelia burgdorferi 16S rRNA gene was detected. Sanger sequencing is considered the gold standard for nucleic acid-based diagnosis of infectious diseases because every distinct species of microorganism has its own unique, defining chromosomal DNA sequence.


Using Sanger sequencing as the tool, a Milford Molecular Diagnostics Laboratory 2023 study [9] showed that the Lyme disease spirochetes can invade the blood stream of the patients during the very early stage of infection, even before any symptoms appear. At this early stage of Lyme disease, there may be less than 1 spirochete in 1 mL of circulating blood. Since the Lyme disease spirochetes tend to attach to and invade lymphocytes in the test tube [10], immediate separation of the B. burgdorferi bacteria into the cell-free platelet-rich plasma after venous blood collection is crucial for successful detection [9]. Because of their similar weights, Borrelia spirochetes can be concentrated in the platelet fraction during

differential centrifugation of the whole blood. Using the entire DNA content extracted from the platelet pellet for PCR amplification without purification can detect a single spirochete in the blood specimen [9].

A lymphocyte has about 6-billion base pairs of individual nucleotides in its nucleus and human genomic nucleotides are potent PCR inhibitors. Once a spirochete has attached to a lymphocyte, it is very difficult to use PCR to selectively amplify a small (about 400 base pairs) segment of the spirochete chromosome DNA. This is why most PCR methods fail to diagnose early localized Lyme disease spirochetemia.

A recent landmark discovery by Milford Molecular Diagnostics Laboratory is the presence of flaB gene paralogs (duplicate genes in a single genome) in the B. burgdorferi spirochetes invading blood stream during the early localized stage of Lyme disease [9]. Since there are more copies of flaB gene than the 16S rRNA gene in a chromosome, flaB gene is a more sensitive molecular target of PCR/Sanger sequencing-based diagnostics for B. burgdorferi spirochetemia [9]. However, clinical Lyme disease in the United States can also be caused by B. mayonii, B. miyamotoi and a novel Borrelia (GenBank Seq ID KM052618). The PCR specifically designed for the detection of B. burgdorferi flaB gene cannot amplify the flaB genes of the latter group of Borrelia species. Therefore, a parallel split sample PCR for Borrelial 16S rRNA gene amplification is instituted [9] in case the clinical Lyme disease is caused by other species of Borrelia whose 16S rRNA genes can be amplified by a single PCR [4, 5, 8].

The diagnosis of Lyme disease is usually initiated by vigilant informed patients living in endemic regions. Ideally, like all other bacteremias Lyme disease spirochetemia should be diagnosed at the hospital laboratories located in the endemic regions. Culturing B. burgdorferi for routine diagnosis is not practical because of its slow growth rate. A sensitive and specific PCR followed by Sanger sequencing for confirmation of the PCR products is an acceptable option. The PCR/Sanger sequencing method developed by Milford Molecular Diagnostics Laboratory has been approved under the CLIA program and by the New York State Department of Health. But we really do not know the duration in which spirochetes are circulating in the blood stream of the patient after the initial infection. In practice, the platelet-rich plasma samples of the patients suspected of having spirochetemia can be frozen for retrospective testing in case the clinical diagnosis of Lyme disease is in doubt. Sending the platelet-rich plasma specimens to another laboratory for PCR/sequencing is acceptable. The anticoagulant agent, ethylenediaminetetraacetic acid (EDTA), in the platelet-rich plasma is bacteriostatic; it can prevent overgrowth of contaminating bacteria during transit at ambient temperature.

Interested persons can Google search (AI mode) with the words of “Sanger Sequencing of Borrelia burgdorferi flaB Paralogs Detected Spirochetemia at the Early Localized Stage of Lyme Disease” and “Sanger sequencing diagnosis of early localized Lyme disease spirochetemia” for more information.

References

1.   Horn EJ, et al. Evaluation of standard and modified two-tiered testing algorithms using well-characterized        early Lyme disease samples. J Clin Microbiol. 2026;64:e0118725.

2.   Lee SH, et al. Increased Sensitivity and Specificity of Borrelia burgdorferi 16S Ribosomal DNA Detection.        Am J Clin Path. 2010; 133:569-576.

3.   Lee SH, et al. Early Lyme disease with spirochetemia – diagnosed by DNA sequencing. BMC Res Notes.          2010; 3:273.

4.   Lee SH, et al. Detection of Borreliae in Archived Sera from Patients with Clinically Suspect Lyme Disease.        International Journal of Molecular Sciences. 2014; 15:4284-4298.

5.   Lee SH, et al. DNA Sequencing Diagnosis of Off-Season Spirochetemia with Low Bacterial Density in              Borrelia burgdorferi and Borrelia miyamotoi Infections. International Journal of Molecular Sciences.                2014;      15:11364-11386.

6.   Lee SH. Lyme disease caused by Borrelia burgdorferi with two homeologous 16S rRNA genes: a case              report. International Medical Case Reports Journal. 2016; 9:101–106.

7.   Lambert JS, et al. Metagenomic 16S rRNA gene sequencing survey of Borrelia species in Irish samples of       Ixodes ricinus ticks. PLoS One. 2019;14:e0209881.

8.  Lee SH, et al. Single Core Genome Sequencing for Detection of both Borrelia burgdorferi Sensu Lato and         Relapsing Fever Borrelia Species. Int J Environ Res Public Health. 2019;16: E1779.

9.  Lee SH. Sanger Sequencing of Borrelia burgdorferi flaB Paralogs Detected Spirochetemia at the Early             Localized Stage of Lyme Disease. Front Biosci (Schol Ed). 2025;17:31280.

10. Dorward DW, et al. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme           disease. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America.       1997; 25: S2–S8.


(See more information on our Lyme Disease DNA testing page)  


Loading

Early Lyme Disease Laboratory Diagnosis



Lyme disease, a systemic bacterial infection caused by Borrelia burgdorferi (B. burgdorferi), is the most common tickborne disease in the United States. Released 2010–2018 insurance records suggest that each year approximately 476,000 Americans are diagnosed and treated for Lyme disease. But the true number of Lyme disease patients is unknown due to the lack of reliable sensitive and specific routine laboratory diagnostic tools. It is believed that at the early stage of infection this disease can be treated successfully with a proper course of antibiotics, but the spirochete bacteria may disseminate from the site of the tick bite to other regions of the body if not timely and properly treated. In the opinion of a group of experts, common FDA-cleared serology tests miss a large number of early Lyme disease cases, and novel diagnostics that improve laboratory confirmation for early Lyme disease are urgently needed [1]. Now, this need has been met by Sanger sequencing of specific B. burgdorferi chromosomal genes in patient’s platelet pellets.


For the past 20 years, the scientists in Milford Molecular Diagnostics Laboratory, formerly affiliated with Milford Hospital in Connecticut, have focused on developing Sanger sequencing methods for routine diagnosis of infectious diseases, in particular for Lyme disease [2-9]. To perform diagnostic Sanger sequencing, one must first extract the nucleic acids from a complex human specimen and use polymerase chain reaction (PCR) to selectively amplify (exponentially duplicate) a segment of the pathogen’s nucleic acid many billion-folds, and use the amplified pathogen DNA as the template for sequencing. The sequencing instrument computer generates an electropherogram as one illustrated below, for example, showing the four-letter nucleotide base sequence. Submission of this 311-base sequence to the GenBank for an enquiry induces a GenBank report confirming that a segment of Borrelia burgdorferi 16S rRNA gene was detected. Sanger sequencing is considered the gold standard for nucleic acid-based diagnosis of infectious diseases because every distinct species of microorganism has its own unique, defining chromosomal DNA sequence.

Using Sanger sequencing as the tool, a Milford Molecular Diagnostics Laboratory 2023 study [9] showed that the Lyme disease spirochetes can invade the blood stream of the patients during the very early stage of infection, even before any symptoms appear. At this early stage of Lyme disease, there may be less than 1 spirochete in 1 mL of circulating blood. Since the Lyme disease spirochetes tend to attach to and invade lymphocytes in the test tube [10], immediate separation of the B. burgdorferi bacteria into the cell-free platelet-rich plasma after venous blood collection is crucial for successful detection [9]. Because of their similar weights, Borrelia spirochetes can be concentrated in the platelet fraction during differential centrifugation of the whole blood. Using the entire DNA content extracted from the platelet pellet for PCR amplification without purification can detect a single spirochete in the blood specimen [9].


A lymphocyte has about 6-billion base pairs of individual nucleotides in its nucleus and human genomic nucleotides are potent PCR inhibitors. Once a spirochete has attached to a lymphocyte, it is very difficult to use PCR to selectively amplify a small (about 400 base pairs) segment of the spirochete chromosome DNA. This is why most PCR methods fail to diagnose early localized Lyme disease spirochetemia.

A recent landmark discovery by Milford Molecular Diagnostics Laboratory is the presence of flaB gene paralogs (duplicate genes in a single genome) in the B. burgdorferi spirochetes invading blood stream during the early localized stage of Lyme disease [9]. Since there are more copies of flaB gene than the 16S rRNA gene in a chromosome, flaB gene is a more sensitive molecular target of PCR/Sanger sequencing-based diagnostics for B. burgdorferi spirochetemia [9]. However, clinical Lyme disease in the United States can also be caused by B. mayonii, B. miyamotoi and a novel Borrelia (GenBank Seq ID KM052618). The PCR specifically designed for the detection of B. burgdorferi flaB gene cannot amplify the flaB genes of the latter group of Borrelia species. Therefore, a parallel split sample PCR for Borrelial 16S rRNA gene amplification is instituted [9] in case the clinical Lyme disease is caused by other species of Borrelia whose 16S rRNA genes can be amplified by a single PCR [4, 5, 8].

The diagnosis of Lyme disease is usually initiated by vigilant informed patients living in endemic regions. Ideally, like all other bacteremias Lyme disease spirochetemia should be diagnosed at the hospital laboratories located in the endemic regions. Culturing B. burgdorferi for routine diagnosis is not practical because of its slow growth rate. A sensitive and specific PCR followed by Sanger sequencing for confirmation of the PCR products is an acceptable option. The PCR/Sanger sequencing method developed by Milford Molecular Diagnostics Laboratory has been approved under the CLIA program and by the New York State Department of Health. But we really do not know the duration in which spirochetes are circulating in the blood stream of the patient after the initial infection. In practice, the platelet-rich plasma samples of the patients suspected of having spirochetemia can be frozen for retrospective testing in case the clinical diagnosis of Lyme disease is in doubt. Sending the platelet-rich plasma specimens to another laboratory for PCR/sequencing is acceptable. The anticoagulant agent, ethylenediaminetetraacetic acid (EDTA), in the platelet-rich plasma is bacteriostatic; it can prevent overgrowth of contaminating bacteria during transit at ambient temperature.


Interested persons can Google search (AI mode) with the words of “Sanger Sequencing of Borrelia burgdorferi flaB Paralogs Detected Spirochetemia at the Early Localized Stage of Lyme Disease” and “Sanger sequencing diagnosis of early localized Lyme disease spirochetemia” for more information.


References


1.   Horn EJ, et al. Evaluation of standard and modified two-tiered testing algorithms using well-characterized        early Lyme disease samples. J Clin Microbiol. 2026;64:e0118725.

2.   Lee SH, et al. Increased Sensitivity and Specificity of Borrelia burgdorferi 16S Ribosomal DNA Detection. Am J Clin Path. 2010; 133:569-576.

3.   Lee SH, et al. Early Lyme disease with spirochetemia – diagnosed by DNA sequencing. BMC Res Notes.         2010; 3:273.

4.   Lee SH, et al. Detection of Borreliae in Archived Sera from Patients with Clinically Suspect Lyme Disease.        International Journal of Molecular Sciences. 2014; 15:4284-4298.

5.   Lee SH, et al. DNA Sequencing Diagnosis of Off-Season Spirochetemia with Low Bacterial Density in              Borrelia burgdorferi and Borrelia miyamotoi Infections. International Journal of Molecular Sciences.                2014;15:11364-11386.

6.   Lee SH. Lyme disease caused by Borrelia burgdorferi with two homeologous 16S rRNA genes: a case              report. International Medical Case Reports Journal. 2016; 9:101–106.

7.   Lambert JS, et al. Metagenomic 16S rRNA gene sequencing survey of Borrelia species in Irish samples of       Ixodes ricinus ticks. PLoS One. 2019;14:e0209881.

8.  Lee SH, et al. Single Core Genome Sequencing for Detection of both Borrelia burgdorferi Sensu Lato and         Relapsing Fever Borrelia Species. Int J Environ Res Public Health. 2019;16: E1779.

9.  Lee SH. Sanger Sequencing of Borrelia burgdorferi flaB Paralogs Detected Spirochetemia at the Early             Localized Stage of Lyme Disease. Front Biosci (Schol Ed). 2025;17:31280.

10. Dorward DW, et al. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme           disease. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 1997; 25: S2–S8.


(See more information on our Lyme Disease DNA testing page)